Loading patent…
AssigneesSorbonne Universite, Assistance Publique-Hopitaux de Paris
InventorAlexandre Carpentier
Estimating the term…
The present invention relates to an ultrasound contrast agent for use in treating a retina disorder by transiently disrupting the blood-retinal barrier (BRB) of a human, wherein the ultrasound contrast agent is administered just before and/or during the application, to the retina of the human, of an unfocused ultrasound (US) beam. The present invention further relates to a therapeutically active agent for use in treating a retina disorder in a human, wherein the therapeutically active agent is to be delivered in combination with an ultrasound contrast agent, which is administered before and/or during the application, to the retina of the human, of an unfocused ultrasound (US) beam in order to transiently disrupting the blood-retinal barrier (BRB) of the human, to allow the therapeutically active agent to cross the BRB and to target the retina. The present invention also relates to an eye ultrasound delivery device that may be used to treat a retina disorder.
A method for treating a retina disorder by transiently disrupting the blood-retinal barrier (BRB) of a human, wherein an ultrasound contrast agent is administered before and/or during the application, to the retina of the human, of an unfocused ultrasound (US) beam.
A method for treating a retina disorder in a human, wherein a therapeutically active agent is to be delivered in combination with an ultrasound contrast agent, which is administered before and/or during the application, to the retina of the human, of an unfocused ultrasound (US) beam in order to transiently disrupting the blood-retinal barrier (BRB) of the human, to allow the therapeutically active agent to cross the BRB and to target the retina.
Eye ultrasound (US) delivery device, comprising at least two unfocused plan US transducers disposed on a substrate suitable to be applied on the cornea of a human to target the retina of a human, wherein the unfocused US transducers can be activated sequentially.
Dependencies are inferred from the claim text.